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Human umbilical cord blood-derived mesenchymal stem 
cells (MSCs) are known to possess the potential for multiple 
differentiations abilities in vitro and in vivo. In canine system, 
studying stem cell therapy is important, but so far, stem cells 
from canine were not identified and characterized. In this 
study,  we  successfully  isolated  and  characterized  MSCs 
from the canine umbilical cord and its fetal blood. Canine 
MSCs  (cMSCs)  were  grown  in  medium  containing  low 
glucose DMEM with 20% FBS. The cMSCs have stem cells 
expression patterns which are concerned with MSCs surface 
markers by fluorescence- activated cell sorter analysis. The 
cMSCs had multipotent abilities. In the neuronal differentiation 
study,  the  cMSCs  expressed  the  neuronal  markers  glial 
fibrillary acidic protein (GFAP), neuronal class III β tubulin 
(Tuj-1),  neurofilament  M  (NF160)  in  the  basal  culture 
media. After neuronal differentiation, the cMSCs expressed 
the neuronal markers Nestin, GFAP, Tuj-1, microtubule- 
associated protein 2, NF160. In the osteogenic & chondrogenic 
differentiation studies, cMSCs were stained with alizarin 
red and toluidine blue staining, respectively. With osteogenic 
differentiation,  the  cMSCs  presented  osteoblastic 
differentiation genes by RT-PCR. This finding also suggests 
that  cMSCs  might  have  the  ability  to  differentiate 
multipotentially. It was concluded that isolated MSCs from 
canine  cord  blood  have  multipotential  differentiation 
abilities. Therefore, it is suggested that cMSCs may represent 
a be a good model system for stem cell biology and could be 
useful as a therapeutic modality for canine incurable or 
intractable diseases, including spinal cord injuries in future 
regenerative medicine studies.
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Introduction 
Mesenchymal stem cells (MSCs) are defined to be 
multipotent stem cells that can be differentiated into various 
type of cells such as, neuronal cells, chondrocytes, adipocytes, 
cardiomyocytes and osteoblasts in vitro and in vivo under 
controlled conditions [15,24,27]. These cells can be isolated 
from many kinds of tissues, including fat, skin, and even the 
brain [2,13,18,22]. However, the most common source to 
obtain these cells is bone marrow. Isolation and 
transplantation of hematopoietic stem cells (HSCs) from 
human bone marrow into the bone marrow of a leukemia 
patient is now a feature of stem cell therapy. To perform this 
therapy it is difficult to find an appropriate immune matched 
donor for the transplantation, and the therapy is still 
recognized to be intricate [5]. MSCs isolated from human 
umbilical cord blood represent an alternative source of 
HSCs. The dog has been considered an attractive animal 
model to evaluate new drugs or medical trials for preclinical 
purposes [23,30]. One advantage of using dogs is that 
canine model transplantation uses a large size animal [9]. 
The isolation and characterization of CD34+ cells from 
canine bone marrow to optimize the conditions for bone 
marrow derived CD34+ cells transplantation has been 
studied [31]. Bhattacharya and colleagues identified 
isolated CD34+ cells from canine bone marrow that had 
endothelialized into the grafted area [3]. However, there 
are few studies on canine umbilical cord blood derived 
MSCs. These cells should be of use for cell based therapies 
and tissue engineering which have been performed in trials 
to overcome the difficulties of gene based therapies and 
their medical limitations. The use of stem cell implantation 
has been increasing, and it is strongly suggested that its use 
may enable an improved treatment of some incurable 
diseases such as genetic disorders [26], spinal cord injuries 
[11] and bone fracture malignancies [25,35]. 
For the past few years, it has been clearly recognized that 182    Min-Soo Seo et al.
MSCs possess immune regulatory properties [1,8]. Adult 
stem cells are known to have a limited differentiation 
potential while embryonic stem cells are totipotent. 
Multipotent stem cells were first isolated from adult bone 
marrow [17]. The multipotent stem cells have been 
isolated and characterized from other adult tissues by 
several investigators [32]. In the present study, we 
successfully isolated and characterized umbilical cord 
blood-derived multipotent stem cells from dogs. The 
characterization conditions and basic settings for the 
application of gene delivery were also investigated.
Materials and Methods
Cell isolation and culture
Canine umbilical cord blood (cUCB) and blood of the 
canine fetus heart using paracentesis was drawn and used 
for the isolation of mononuclear cells. The collected blood 
was delivered in tubes treated with EDTA as an anti- 
coagulant. Blood was diluted 1 : 1 with PBS (Cellgro, 
USA). A density gradient using Ficoll-paque (GE Healthcare, 
USA) was sperformed to collect the buffy coat layer. 
Mononucleated cells were seeded into T75 cell culture 
flasks (Nunc, USA) at 5 × 10
6 cells/mL. Three days after 
the cells were seeded, they were transferred to new flasks 
containing half the amount of Dulbeco’s Modified Eagle’s 
Medium (low glucose DMEM; Gibco BRL, USA). The 
adhered cells were trypsinized to maintain passage after 7 
days that the primary cells were seeded. 
Cell expansion
Cumulative population doubling level (CPDL) was 
calculated using the formula “x = {log10(NH)−log10 
(N1)}log10” [6] where N1 is the inoculum cell number and 
NH is the cell harvest number. To yield the cumulated 
doubling level, the population doubling for each passage 
was calculated and then added to the population doubling 
levels of the previous passages. As the cell number of 
isolated cells of all three tissues could be determined for 
the first time at passage 1, the cumulative doubling number 
was first calculated for passage 1 for this result. 
Neurogenic differentiation
The cUCB-MSCs were seeded into a low-glucose DMEM 
with 20% FBS to confluent population. Cells were 
preincubated for 24 h with 1 mM Beta-mercaptoethanol and 
20% FBS. After preincubation, cells were transferred to 
induction medium constituted with 100 μM Docosahexaenoic 
(Sigma, USA), B27 supplement (Gibco, USA) and 1.5% 
Dimethyl sulfoxide (Sigma, USA) serum free for 2 days [19].
Osteogenic differentiation
Adherent cells were cultured in osteogenic medium 
composed of LG-DMEM supplemented with 10% FBS, 10 
mM β-glycerophosphate, 0.1 μM dexamethasone (Sigma- 
Aldrich, USA), and 50 μM ascorbic acid-2-phophate for 
30 days. Osteogenic differentiation was evaluated by 
calcium mineralization. Alizarin red S staining was used 
to determine the presence of calcium mineralization. For 
Alizarin red S staining, cells were washed with D.W 2 
times and fixed in a solution of ice-cold 70% ethanol for 1 
h. After carefully washing 7 times with D.W, cells were 
stained for 10 min with 40 mM Alizarin red S after washed 
with D.W for 2 times in room temperature [10,29].
Chondrogenic differentiation
Chondrogenic differentiation was followed as previously 
described [14,29]. Briefly, 5 × 10
5 cells were seeded in a 
15-mL polypropylene tube and centrifuged to a pellet. The 
pellet was cultured at 37
oC in a 5% CO2 incubator in 1 mL 
of chondrogenic medium that contained 500 ng/mL bone 
morphogenetic protein-2 (BMP-2; R&D Systems, USA) 
for 3 weeks. The chondrogenic differentiation medium 
[DMEM with 10% FBS] was replaced every 3 days with 
fresh medium. The pellets were embedded in paraffin and 
cut into 3 μm sections. For histological evaluation, the 
sections were stained with toluidine blue following general 
precedures. 
Fluorescence-activated cell sorter (FACS) analysis
Cultured canine cord blood derived mononucleated cells 
were collected from each passage, washed in PBS, counted 
and aliquots of approximately 1 × 10
6 cells for each 
antibody were obtained. Mouse anti-canine CD4, mouse 
anti-canine CD8a, mouse anti-canine CD10 (Serotec, 
USA), mouse anti-canine CD14, mouse anti-canine CD20, 
mouse anti-canine CD24, mouse anti-canine CD29, mouse 
anti-canine CD31, mouse anti-canine CD33, R-phycoerythrin- 
conjugated mouse anti-canine CD34 (BD Biosciences, 
USA), mouse anti-canine CD38, mouse anti-canine 
CD41a, mouse anti-canine MHC II (HLA-DR alpha), rat 
anti-mouse CD44 endothelium, mouse anti-canine CD45, 
mouse anti-canine 49b, mouse anti-canine CD 51/61, 
mouse anti-canine CD62p, mouse anti-canine CD73, 
mouse anti-canine CD90, mouse anti-canine CD105, 
mouse anti-canine CD133, mouse anti-canine CD133, 
mouse anti-canine CD184, Flurescein-labeled affinity 
purified antibody to rat IgG (H+L), Flurescein-labeled 
affinity purified antibody to mouse IgG (H+L) (KPL, 
USA) were used for cell surface antigen detection. 
Analysis was evaluated by the use of FACS Calibur (BD 
Biosciences, USA) and Cell Quest Pro (BD Biosciences, 
USA) software.
Immunostaining
Immunostaining was carried out as previously reported 
[16]. Antibodies used were rabbit anti-Nestin (Nestin; 
Santa Cruz Biotechnology, USA), mouse anti-glial fibrillary Isolation and characterization of canine umbilical cord blood-derived mesenchymal stem cells     183
Fig. 1. Identification of the cumulative population doubling 
level (CPDL) and culture of canine umbilical cord blood 
(cUCB)-mesenchymal stem cells (MSCs). Cells were cultured in 
DMEM (with 20% FBS). A: Two bars in a graph indicate the 
CPDL increase. Both bars show a consistently increasing growth 
rate during the passages. Each bar increase originates from the 
CPDL cumulative values, which were two separated sampled 
cells. B: Phase-contrast image of cUCB-MSCs, ×200.
acidic protein (GFAP; Chemicon, USA), rabbit anti- 
microtubule-associated protein 2 (MAP2; Chemicon, 
USA), mouse anti-neuronal class III β tubulin (Tuj-1; 
Covance, UK) and mouse anti-neurofilament M (NF160; 
Chemicon, USA). For immunostaining, cells were fixed in 
4% paraformaldehyde for 15 min, and then permeabilized 
for 10 min at room temperature in 0.4% Triton-X 100 
diluted in PBS. After washing 3 times, cells were blocked 
with normal goat serum overnight at 4
oC. Cells were 
incubated with primary antibodies overnight at 4
oC. After 
washing 3 times, the cells were incubated with secondary 
antibodies Alexa 488 & 594 (1 : 1,000; Molecular Probe, 
USA) for 1 h. Finally, for nuclear staining, Hoechst 33238 
(1 mg/mL) was diluted 1 : 100 in PBS and loaded into 
samples for 15 min. Images were captured on a confocal 
microscope (Eclipse TE200; Nikon, Japan).
Reverse transcriptase polymerase chain reaction
Total RNA was isolated from the cUCB-MSCs using 
TRIzol (Invitrogen, USA). RNA concentrations were measured 
by absorbance at 260 nm with a spectrophotometer, and 2 μg 
total RNA was used for reverse transcription using 
Superscript II reverse transcriptase (Invitrogen, USA). The 
cDNA was amplified using Taq Platinum (Invitrogen, 
USA). The primers used were designed according to the 
following oligonucleotide primers: homeobox gene MSX2 
(MSX2) (sense, 5´-TCCGCCAGA AACAATACCTC-3´; 
antisense, 5´-AAGGGTAGGACGCTCCGTAT-3´), collagen 
1A1 (COL1A1) (sense, 5´-CACCTCAGGAGAAGGCTC 
AC-3´; antisense, 5´-ATGTTCTCGATCTGCTGGCT-3´), 
osteonectin (SPARC) (sense, 5´-TGAGAAGGTATGCAG 
CAACG; antisense, 5´-AGTCCAGGTGGAGTTTGTGG), 
vitamin D receptor (VDR) (sense, 5´-CCAATCTGGATCTG 
AGGGAA; antisense, 5´-TTCAGCAGCACAATCTGGTC- 
3´), and osteoclacin (BGLAP) (sense, 5´-GTGGTGCAAC 
CTTCGTGTC; antisense, 5´-GCTCGCATACTTCCCTCTT 
G-3´). Canine glyceraldehyde-3-phosphate dehydrogenase 
primers (sense, 5´-AACATCATCCCTGCTTCCAC-3´; 
antisense, 5´-TCCTTGGAGGCCATGTAGAC-3´) were 
used as internal control for polymerase chain reactions 
(PCRs). The RNA templates were amplified at 33 to 45 
cycles of 94
oC (30 sec), 58
oC to 61
oC (30 sec), 72
oC (1 
min), followed with 72
oC for 10 min. PCR products were 
visualized with ethidium bromide on a 3% agarose gel.
Results
Cell culture & cell growth kinetics and CPDL
We isolated cUCB-MSCs from canine umbilical cord 
blood following to the cell isolation & culture method. The 
cUCB-MSCs (1 × 10
6) were collected and assessed in a 
T-25 cell culture flask. The passaged cells were collected 
every 2 days to count the cell number. The CPDL was 
measured and calculated and drawn as a graph. A 
consistently increasing rate of growth of the cumulative 
population was seen. Cells were cultured and maintained 
until passage 11. Small colonized populations were 
observed at the early stages of culture and dissociated for 
passaging. For each of the passages 1 to 11, cells were 
cryopreserved for further passaging and experiments (Fig. 
1A). The morphology of cells was spindle-shape and 
typical fibroblast-like shape (Fig. 1B)
Immunophenotypical characteristics determined by 
FACS analysis
 To detect surface markers and characterize the cUCB- 
MSCs, we performed FACS analyses of cUCB-MSCs at 
the passage 3, showing positive expressions for CD29, 
CD33, CD44, CD105, CD184 and Oct4, whereas the 
following were negatively expressed: CD4, CD8a, CD10, 
CD14, CD20, CD24, CD31, CD34, CD38, CD41a, CD45, 
CD49b, CD41/61, CD62p, CD73, CD90, CD133 and 
HLA-DR (Table 1). The expression patterns of the 
immunophenotyping with cUCB-MSCs revealed that the 184    Min-Soo Seo et al.
Fig. 2. Immunostaining of undifferentiated and neuronal differentiated cUCB-MSCs. cUCB-MSCs were immunostained with glial 
fibrillary acidic protein (GFAP), microtubule-associated protein 2 (MAP2), neuronal class III β tubulin (Tuj-1), Nestin and 
neurofilament M (NF160). Negative control was confirmed with Alexa 488 (green) and Alexa 594 (red). A: The cells were cultured with
basal cultured media. B: The cells were cultured with neuronal differentiation media. C-H: Comparing to basal culture condition 
(undifferentiation) with neuronal differentiation condition. C, E and G: Undifferentiation; D, F and H: Neuronal differentiation. Nestin,
Tuj-1 and NF160 were green. GFAP and MAP2 were red. Scale bars = 50 μm.
Table 1. Fluorescence-activated cell sorter analysis of canine 
UCB-mesenchymal stem cells
Marker Percentage Marker Percentage
CD4 14.5 CD44 69.79
CD8a   1.67 CD45   0.01
CD10 15.18 CD49b 11.65
CD14   0.73 CD51/61 20.96
CD20   1.31 CD62p   0.25
CD24 16.56 CD73 0.39
CD29 60.11 CD90   0.05
CD31   0.03 CD105 94.07
CD33 64.93 CD133   0.73
CD34   0.01 CD184 79.35
CD38   0.03 HLA-DR   0.15
CD41a   0.02 Oct4 99.72
Cells were identified for expression against a series of CD antibodies
immune receptors. Grey boxes indicate positive expression markers.
cells were positive for many common MSC markers [37] : 
CD29, CD44, CD105. Also the cUCB-MSCs strongly 
expressed the embryo stem cells associated surface marker 
[37]: Oct4. The cUCB-MSCs had negative expression 
patterns for the hematopoietic surface markers of CD14, 
CD34 and CD45. 
Differentiation study of the neuronal induction
Neuronal differentiation was examined according to the 
neuronal induction method. The cUCB-MSCs showed 
basically neuronal associated protein markers in the basal 
culture status. In the undifferentiated condition, the cUCB- 
MSCs slightly expressed GFAP, Tuj-1, and NF160 neuronal 
cell protein markers. However, the cUCB-MSCs did not 
express about Nestin and MAP2 (Fig. 2A). When inducted 
with neuronal differentiation media, the cUCB-MSCs 
showed positive expression patterns for Nestin, GFAP, 
Tuj-1, MAP2 and NF160 (Fig. 2B). Compared to the basal 
culture condition, the cUCB-MSCs had positive for 
Nestin, MAP2 with neuronal induction, but were negative 
prior to differentiation. These data showed that cUCB- 
MSCs had the ability to be inducted into glial and neuron 
cells under differentiation conditions (Figs. 2A-H). 
Differentiation study of osteogenic and chondrogenic 
induction
To show osteogenesis, the cUCB-MSCs were culture in 
the osteogenic induction media. Osteogenic induction Isolation and characterization of canine umbilical cord blood-derived mesenchymal stem cells     185
Fig. 3. Osteogenic and chondrogenic differentiation of cUCB-MSCs. A-C: Osteogenic differentiation. A and B: Alizarin red S 
staining. A: Undifferentiation (UDF), B: Differentiation (DF), C: RT-PCR. (D-F) Chondrogenic differentiation. D: Pellet formation; E 
and F: Toluidine blue stain. A: ×200, B: ×200, E: ×100, F: ×200.
medium was changed every 3 days for 3 weeks. Calcium 
mineralization forms were detected on the induced cells to 
show a significant difference compare to the undifferentiated 
cells, which did not show any changes (Fig. 3A). Alizarin 
red staining was positive after 3 weeks under osteogenic 
induction media (Fig. 3B). Also, gene expression of 
markers associated with osteoblastic differentiation such 
as MSX2, COL1A1, SPARC, VDR and BGLAP was 
evident when compared to basal culture condition. The 
cUCB-MSCs had a strongly positive MSX2 expression. 
After osteogensis, osteoblastic gene markers such as 
COL1A1, SPARC, VDR and BGLAP were abundantly 
increased except MSX2, which was steadily expressed 
(Fig. 3C). However, other osteoblastic differentiation 
markers, alkaline phosphatase and osteopontin, did not 
appear both in the basal culture and osteogenic differentiation 
conditions (data not shown).
To investigate the chondrogenesis, the cUCB-MSCs were 
seeded into 15-mL polypropylene tubes and centrifuged to 
a pellet. The pellet was cultured at 37°C in a 5% CO2 
incubator in 1 mL of chondrogenic medium changed every 
3 days for 2∼3 weeks. The pellet was white in color and 
had atransparent structure. The pellet formed aggregates in 
the bottom of the tube (Fig. 3D), and positive to toluidine 
blue staining (Figs. 3E and F).
Discussion
Isolation and characterization of stem cells derived from 
various tissues and sources have been one very critical 
issue for stem cell therapy [12,28,33]. The purpose of this 
study was to isolate, characterize, and differentiate canine 
umbilical cord blood-derived mesenchymal stem cells. We 
cultured cUCB-MSCs with basal culture medium (DMEM 
with 20%FBS) for 11 passages to show that the cUCB- 
MSCs could be cultured successfully and expanded in 
vitro. The morphology of the cUCB-MSCs showed typical 
mesenchymal cells along with fibroblastoid and spindle 
shape, plastic-adherence character. The immunophenotype 
of cUCB-MSCs expressed mesenchymal stem cells 
surface markers such as CD29, CD44 and CD105. 
However, the cUCB-MSCs had negative expressions of 
hematopoietic surface markers of CD14, CD34 and CD45. 
The cUCB-MSCs had the multipotent ability to 
differentiate into neuronal cells, osteocytes and chondrocytes. 
In our differentiation studies, we tried to induce adipogenesis 
with the cUCB-MSCs. However, the cUCB-MSCs did not 
appear to be able to differentiate into adipocytes, with 
non-morphological changes on containing oil droplets for 
4 weeks (data not shown). The cUCB-MSCs were able to 
differentiate into neuronal cells, positively expressing 
neuronal protein markers such as GFAP, Tuj-1 and NF160. 
This observation and the reports that undifferentiated stem 
cells express neuron markers [7] explains the possibility of 
stem cells possessing a neural progenitor’s characteristics. 
A similarity between various tissues has been observed in 
previous studies [20,21]. We also found the undifferentiated 
cells could be driven to osteogenic lineaged cells, with 
calcium deposition after differentiation induction. Also, 
cUCB-MSCs can undergo chondrogenic differentiation as 
shown in pellet formation and toluidine blue staining. In 
this study, we used cUCB-MSCs at 3∼5 passage. Generally, 
increasing the passage number of adult stem cells often 
leads to a decline in the multipotent abilities [36]. Human 
mesenchymal stem cells could be proliferated and have 
differentiation abilities at least 15 passages [34].186    Min-Soo Seo et al.
A typical fibroblastoid morphology was observed in the 
isolated and maintained cultures, which is commonly 
observed in human umbilical cord blood derived MSCs 
[4]. A rapid growth rate is an intrinsic aspect of cultured 
cUCB-MSCs [4]. Cytotherapy using human umbilical 
cord blood stem cells frequently has encountered a number 
of obstacles with the number of available cells for analysis. 
There are large difficulties in isolating enough multipotent 
stem cells from human umbilical cord blood and maintaining 
cell culture for experimental analysis. A guarantee of 
enough numbers of multipotent stem cells out of a very 
small quantity of cord blood sample from the canine 
umbilical cord blood is attractive. 
In conclusion, this study provides a simplified isolation 
and characterization procedure for mesenchymal stem 
cells derived from canine umbilical cord blood, which can 
differentiate into neuronal cells, osteocytes and chondrocytes. 
This study suggests that the cUCB-MSCs have the 
potential to be a resource for stem cell therapy and 
regenerative medicine in a canine animal model system. 
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